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Human cytomegalovirus (HCMV) encodes a G protein-
coupled receptor (GPCR), named US28, which shows
homology to chemokine receptors and binds several
chemokines with high affinity. US28 induces migration
of smooth muscle cells, a feature essential for the devel-
opment of atherosclerosis, and may serve as a co-recep-
tor for human immunodeficiency virus-type 1 entry into
cells. Previously, we have shown that HCMV-encoded
US28 displays constitutive activity, whereas its mamma-
lian homologs do not. In this study we have identified a
small nonpeptidergic molecule (VUF2274) that inhibits
US28-mediated phospholipase C activation in tran-
siently transfected COS-7 cells and in HCMV-infected
fibroblasts. Moreover, VUF2274 inhibits US28-mediated
HIV entry into cells. In addition, VUF2274 fully dis-
places radiolabeled RANTES (regulated on activation
normal T cell expressed and secreted) binding at US28,
apparently with a noncompetitive behavior. Different
analogues of VUF2274 have been synthesized and phar-
macologically characterized, to understand which fea-
tures are important for its inverse agonistic activity.
Finally, by means of mutational analysis of US28, we
have identified a glutamic acid in transmembrane 7 (TM
7), which is highly conserved among chemokine recep-
tors, as a critical residue for VUF2274 binding to US28.
The identification of a full inverse agonist provides an
important tool to investigate the relevance of US28 con-
stitutive activity in viral pathogenesis.
Human cytomegalovirus (HCMV)1 is a widespread pathogen
that does not cause significant clinical manifestations in
healthy individuals. In contrast, primary infection or reactiva-
tion of the virus in immunocompromised hosts, such as trans-
plant recipients and AIDS patients, can cause severe and even
fatal disease (1). Moreover, different clinical studies have sug-
gested that HCMV infection plays a role in the development of
vascular diseases including vascular allograft rejection, rest-
enosis, and atherosclerosis (2, 3).
HCMV encodes four putative GPCRs, namely US27, US28,
UL33, and UL78 (4). It is interesting to notice that, like HCMV,
various - and -herpesviruses, such as human herpesviruses
HHV-6, HHV-7, and HHV-8 (Kaposi’s sarcoma associated Her-
pesvirus) also encode GPCRs in their genome (reviewed in Ref.
5). These virally encoded GPCRs show homology to mammalian
chemokine receptors, suggesting that these viruses exploit che-
mokine signaling pathways as a general mechanism to inter-
fere with the host immune system (6).
HCMV-encoded US28 shows high homology to CC-chemo-
kine receptors and binds several CC-chemokines such as CCL5/
RANTES, CCL3/macrophage inflammatory protein 1, and
CCL2/monocyte chemoattractant protein 1 with high affinity
(7, 8). Furthermore, US28 binds the membrane-bound CX3C-
chemokine CX3CL1/fractalkine, which has been suggested to
play a role in the cellular interaction with viral particles (9). It
has been demonstrated that US28 exhibits some HIV entry
cofactor activity when coexpressed with CD4 (10). Moreover, a
recent study (11) has shown that expression of US28 after
infection with HCMV induces smooth muscle cells migration,
providing a potential link between CMV and progression of
vascular disease.
We have recently shown that US28 constitutively signals
through a Gq pathway leading to activation of phospholipase C
(PLC) and the transcription factor NF-B when transiently ex-
pressed in COS-7 cells (12). CC-chemokines such as CCL5/RAN-
TES and CCL2/monocyte chemoattractant protein 1 do not mod-
ulate the basal signal of this receptor, whereas the CX3C-
chemokine CX3CL1/fractalkine inhibits 35% of the US28-
mediated response and is therefore classified as a partial inverse
agonist. The possible implications of the high constitutive activ-
ity of US28 in the pathogenesis of CMV infection have not been
established yet. It can be hypothesized that expression of a GPCR
that functions in the absence of ligands may aid the virus to alter
the normal homeostasis of the host cell for its own benefit. Other
viral-encoded GPCRs, such as KSHV-encoded ORF74 (13) and
RCMV-encoded R33 (14), show constitutive activity as well.
KSHV-encoded ORF74 provides currently the best evidence for
the link between constitutive activity and viral pathology.
ORF74 has oncogenic potential (15) and transgenic mice express-
ing ORF74 develop angioproliferative lesions that morphologi-
cally resemble Kaposi sarcoma (15, 39). Based on these consid-
erations, viral GPCRs, including US28, can be regarded as
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putative new drug targets. In this study we report the identifi-
cation of the first nonpeptidergic molecules able to bind a viral
GPCR (US28) and to inhibit its basal signaling. These molecules
provide valuable tools for the study of the role of US28 in HCMV-
infected cells and serve as potential leads for the development of
a new class of anti-HCMV agents.
MATERIALS AND METHODS
DNA Constructs—The cDNA encoding for US28 (12) was inserted
into the mammalian vector pcDEF3 (kindly provided by Dr. J. Langer).
(2–22)-US28 and the hemagglutinin-tagged versions of both WT- and
(2–22)-US28 were generated by PCR. Single amino acid mutations, as
for E277A- and E277Q-US28, were introduced using the Altered
SitesTM II in vitro Mutagenesis System (Promega, Madison, WI), ac-
cording to the manufacturer’s protocol. All constructs were verified by
dideoxy sequencing.
Synthesis of Compounds—VUF2274 and analogues were synthesized
in-house following previously published methods (16) and confirmed by
NMR analysis.
Cell Culture, Transfection, and Infection with HCMV—COS-7 cells
were grown as previously described (12). Transfection of the COS-7 cells
was performed by DEAE-dextran, using 2 g of DNA of each US28
construct per million cells (12).
A fibroblast cell line established from human foreskin fibroblasts
(HFF) was maintained in minimum essential medium with Earles
salts (Invitrogen) supplemented with 10% heat-inactivated fetal calf
serum (Invitrogen), 10 units/ml penicillin, 100 g/ml streptomycin, 2
mM L-glutamine, and minimal essential medium nonessential amino
acids (Biochrom). Cells were used between passages 14 and 16. HFFs
were infected 24 h after seeding with a multiplicity of infection of 1 with
either the human cytomegalovirus laboratory strain AD169, or a mu-
tant of AD169 (AD169-US28) in which the nucleotide sequence of
US28 encoding residues 78 to 321 was deleted by restriction endonu-
clease digestion.2 The HCMV strain AD169 was obtained from Dr.
Ulrich H. Koszinowski, University of Munich, Munich, Germany. The
AD169-US28 was constructed with the bacterial artificial chromo-
some mutagenesis technology2 and confirmed by RNA analysis.2
[3H]Inositol Phosphate Production—Experiments in COS-7 cells
were performed as previously described (12). 5 h after infection, HFFs
were labeled by incubation in inositol-free Dulbecco’s modified Eagle’s
medium supplemented with 3 Ci/ml myo-[2-3H]inositol for 48 h. Sub-
sequently, the labeling medium was aspirated, cells were washed for 10
min with Dulbecco’s modified Eagle’s medium containing 10 mM LiCl
and incubated for 30 min in the same medium in the absence or
presence of fractalkine (100 nM). Inositol phosphates were extracted
from the cells with the chloroform/methanol method (24) and purified
by anion exchange chromatography (Dowex AG1-X8 columns, Bio-Rad)
and counted by liquid scintillation.
Binding Experiments—Labeling of CCL5/RANTES (Peprotech, Rocky
Hill, NJ) with [125I] and binding in COS-7 cells were performed as previ-
ously described (14). Briefly, in displacement studies transfected COS-7
cells were incubated with 0.3 nM 125I-RANTES in binding buffer (50 mM
Hepes, pH 7.4, 1 mM CaCl2, 5 mM MgCl2, and 0.5% bovine serum albumin)
in the presence or absence of various concentrations of VUF2274 for 3 h at
4 °C. In saturation binding studies, transfected cells were incubated with
different concentrations of 125I-RANTES ranging between 0.1 and 10 nM.
After incubation, cells were washed four times at 4 °C with binding buffer
supplemented with 0.5 M NaCl. Nonspecific binding was determined in
the presence of 0.1 M cold chemokine. Two days after infection, binding
was performed on HFFs as described for COS-7 cells, except that 30 pM
125I-RANTES (PerkinElmer Life Sciences) was used.
HIV-1 Infection Assay—HEK293-T cells were transiently transfected
with pcDNA1-US28 and pcDNA1-CD4 using the calcium phosphate
method and cultured overnight in 48-well plates. The following day,
cells were incubated with different concentrations of VUF2274 (dis-
solved in Me2SO) or medium (containing an equal amount of Me2SO) for
2 h before infection with an R5-tropic HIV-1 virus containing the
luciferase reporter gene under the long term repeat promoter. After
overnight incubation, cells were washed twice and cultivated in fresh
medium. 3 days after infection, the luciferase activity was quantitated
using the luciferase assay system (Promega).
Enzyme-linked Immunosorbent Assay—48 h after transfection, re-
ceptor expression in COS-7 cells was measured with an enzyme-linked
immunosorbent assay as previously described (14). Mouse anti-hemag-
glutinin monoclonal antibody (kindly provided by Dr. J. van Minnen,
Vrije University, Amsterdam, The Netherlands) was used as primary
antibody, and goat anti-mouse horseradish peroxidase conjugate (Bio-
Rad) as secondary antibody. The TMB solution (Sigma) was used as
substrate and the optical density was measured in a Victor2
(PerkinElmer Life Sciences) at 450 nm.
Toxicity Test—The AlamarBlueTM assay (Serotec, Oxford, UK) was
performed following the manufacturer’s protocol. Briefly, transfected
cells were incubated with VUF2274 for 2 h, followed by the addition of
the AlamarBlue dye. After 1 h, the fluorescence was monitored at 560
nm excitation wavelength and 590 nm emission wavelength in a Victor2
(PerkinElmer Life Sciences).
Generation of in Silico Model of US28—An alignment was made
between bovine rhodopsin and US28 using Clustal X. A homology model
of US28 was generated using the homology module of Insight II, version
2.3.0 (Biosym Technologies, San Diego, CA). The A chain from the
crystal structure of bovine rhodopsin was used as a template (18).
Data Analysis—Curve fitting of data was carried out using the pro-
gram Prism and IC50 values were obtained by nonlinear regression
analysis (GraphPad Software, Inc., San Diego, CA). Data are expressed
as mean  S.E.
2 R. Minisini, C. Tulone, A. Lu¨ske, D. Michel, T. Mertens, P.
Gierschik, and B. Moepps, submitted for publication.
TABLE I
Activities of various VUF2274 analogues
VUF2274 analogues were tested for their ability to inhibit US28-mediated InsP production or 125I-RANTES binding. Values are expressed in
micromolar and represent the average of at least two independent experiments. S.E. calculated on the IC50 values is within 0.2. N.A., non active.
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RESULTS
Discovery of a Small Nonpeptidergic Inverse Agonist at
US28—To find inverse agonists for US28, we have screened a
variety of GPCR-directed ligands for modulation of the US28-
mediated constitutive inositol phosphate (InsP) production.
This approach has led us to identify VUF2274 (Table I) as the
inverse agonist for US28. This molecule has previously been
reported (16) as an antagonist for the human chemokine recep-
tor CCR1, which shares 30% homology with US28.
VUF2274 dose dependently inhibits US28-mediated InsP pro-
duction in COS-7 cells (Fig. 1A). VUF2274 inhibits90% of US28
constitutive signaling with an IC50 of 3.5 M (pIC50  5.46 
0.07; where pIC50 representslog(IC50)). VUF2274 did not show
cellular toxicity as determined with the AlamarBlueTM assay
(data not shown). Moreover, other GPCRs were used as controls
to ascertain specificity of action of this compound. As previously
reported, expression of RCMV-encoded R33 (14) or KSHV-en-
coded ORF74 (19) also leads to constitutive activation of phos-
pholipase C. VUF2274 does not modulate R33- or ORF74-medi-
ated PLC activation at concentrations as high as 10 M (Fig. 1B).
Furthermore, VUF2274 was tested on COS-7 cells expressing the
human histamine H1 receptor. Like US28, this GPCR constitu-
tively activates PLC enzymes via Gq/11 proteins (20). VUF2274
(10 M) does not alter basal or histamine-induced production of
InsP in COS-7 cells expressing the H1 receptor (data not shown),
ruling out a possible interference with Gq/11 proteins.
Several analogues of VUF2274 were subsequently synthesized
to unravel some structural features important for its inverse
agonistic effect at US28 (Table I). Variations of the benzhydryl
moiety are well allowed: insertion of an ethylene (VUF5713) or
thiomethylene bridge (data not shown) results in compounds
of comparable potencies, indicating that some flexibility is
tolerated in this part of the template. On the other hand,
replacement of one of the phenyl rings with more hydrophilic
moieties, such as a hydroxyl group (VUF5715), results in a
loss of effect, suggesting that a bulky lypophilic moiety is
important. The nitrile substituent does not appear to play a
role because its removal (VUF5667) does not affect the activ-
ity of the compound. Substitution of the piperidine with a
piperazine ring (VUF5658) results in an inactive compound.
Finally, removal of the hydroxyl group (VUF5662) or the
chlorine substituent (VUF5660) is detrimental to the inverse
agonistic potency, resulting in a 5–10-fold loss in potency. A
complete study of structure-activity relationships is beyond
the scope of this article and will be discussed elsewhere.3
Displacement of Chemokine Binding at US28—VUF2274
dose dependently displaces 125I-RANTES binding to US28 in
transiently transfected COS-7 cells with an IC50 of 8.4 M
(pIC50 5.07 0.1; Fig. 2A). Various VUF2274 analogues were
also tested in 125I-RANTES displacement (Table I). In general,
affinity for US28 correlates well with the potency of these
compounds in the InsP assay.
We further investigated the effect of VUF2274 in a satura-
tion binding assay of 125I-RANTES. In the presence of
VUF2274, the Bmax value of
125I-RANTES is markedly de-
creased (Bmax  725  69 versus 380  36 fmol/mg protein in
the absence and presence of 10 M VUF2274, respectively; Fig.
2B), whereas the Kd is little affected (pKd  8.85  0.01 and
8.78  0.04 in the absence and presence of VUF2274, respec-
tively), suggesting that VUF2274 acts as a noncompetitive
inhibitor. In view of these results, we performed the InsP assay
in the presence of both RANTES and VUF2274, to analyze the
effect of chemokines on VUF2274 inhibition in a functional
assay. RANTES (107 M), previously identified as a neutral
antagonist (12), does not affect the IC50 or maximal inhibition
of US28 signaling mediated by VUF2274 (pIC50  5.51  0.1;
n  2).
Chemokines and VUF2274 Have Different Binding Pockets—
To study which structural elements of US28 are responsible for
interaction with chemokines and VUF2274, different mutant
receptors were generated. The extracellular N-terminal do-
main of chemokine receptors is generally thought to play an
important role in binding of chemokines (21–23). To elucidate
the role of the N terminus of US28 in chemokine binding, we
generated a mutant US28 receptor, which lacks the first 22
amino acids of the N terminus (referred to as (2–22)-US28).
To measure receptor expression in transfected cells, the WT-
and (2–22)-US28 receptors were epitope-tagged at their N
terminus. The hemagglutinin epitope does not alter WT-US28
receptor expression, signaling, or chemokines binding (data not
shown).
The N terminus deletion mutant is expressed at the cell
surface (39  4% compared with WT-US28, n  3) as deter-
mined by enzyme-linked immunosorbent assay. However, (2–
22)-US28 does not bind any of the tested chemokines (125I-
RANTES, Fig. 4A, or 125I-fractalkine, data not shown) at
concentrations as high as 10 nM. (2–22)-US28 still shows con-
stitutive production of InsP (Fig. 3A), proving that truncation of
the N terminus does not affect the correct orientation of the
3 P. Casarosa, J. Hulsof, W. M. Menge, H. Timmerman, M. J. Smit,
and R. Leurs, unpublished data.
FIG. 1. Inhibition of US28-mediated inositol phosphates accu-
mulation by VUF2274. A, COS-7 cells expressing US28 were incu-
bated with various concentrations of VUF2274 and InsP release was
measured. Data are presented as percentage of US28-mediated re-
sponse, defined as the absolute increase of US28-mediated InsP accu-
mulation above values obtained for mock transfected cells. The average
of 11 experiments, with each data point performed in triplicate, is
shown. B, ORF74- and R33-transfected COS-7 cells were incubated
with VUF2274 (10 M) and InsP accumulation was measured. Data are
presented as percentage of the basal signaling of the receptor. The
average of three experiments, with each data point performed in trip-
licate, is shown.
FIG. 2. Displacement of 125I-RANTES binding at US28 by
VUF2274. A, COS-7 cells expressing US28 were incubated with 0.3 nM
125I-RANTES in the presence of various concentrations of VUF2274.
Data are presented as percentage of US28-specific binding. The average
of four experiments, with each data point performed in triplicate, is
shown. B, US28-transfected COS-7 cells were incubated with several
concentrations of 125I-RANTES in the presence (open circles) or absence
(filled circles) of VUF2274 (10 M). Data are presented as specific
binding at US28 (cpm). A representative experiment of three experi-
ments, each performed in triplicate is shown.
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receptor macromolecule at the cell surface. In contrast to WT-
US28, (2–22)-US28 basal signaling is not inhibited by the
CX3C-chemokine fractalkine (Fig. 3A), again indicating the loss
of chemokine binding for this mutant. Yet, VUF2274 totally
inhibits the constitutive signaling of (2–22)-US28 with a similar
potency as observed for WT-US28 (pIC50  5.35  0.1; Fig. 3B).
To characterize the binding site of VUF2274, an in silico
model of US28 was generated based on homology with bovine
rhodopsin (18). Small nonpeptidergic ligands are known to
usually bind within the 7 TM domains of GPCRs (24, 25). We
therefore searched for negatively charged amino acids that
would be in the hydrophilic pocket between the 7 TM domains
as potential interaction partners for the basic nitrogen of the
piperidine moiety of VUF2274, which is predominantly proto-
nated at physiological pH.
A glutamic acid residue in TM-7 (Glu277) appeared as an
interesting candidate for its potential water accessibility.
Glu277 was therefore mutated into glutamine, to eliminate the
charge but retain the hydrogen bonding potential of the side
chain, and into alanine, to eliminate both the charge and the
hydrogen bonding potential. E277A- and E277Q-US28 are ex-
pressed at the membrane surface of COS-7 cells (Bmax  663 
49; 421  45 and 285  57 fmol/mg of protein for WT-, E277A-,
and E277Q-US28, respectively; Fig. 4A) and bind 125I-RANTES
with an affinity comparable with WT-US28 (pKd  8.85  0.1;
8.89  0.1, and 8.90  0.1 for WT-, E277A-, and E277Q-US28,
respectively; Fig. 4A). Interestingly, E277A- and E277Q-US28
constitutively activate PLC in a similar fashion to US28 WT
(InsP levels are, respectively, 73 and 64% of US28 WT, data not
shown). Taken together, these results show that the glutamic
acid residue does not play a critical role for the correct organi-
zation of US28 in its active conformation and in receptor-
chemokine interaction. Interestingly, the affinity of VUF2274
is markedly reduced for both of these mutants when compared
with WT-US28 (Fig. 4B). These results imply that glutamate in
position 277 indeed provides part of the interaction site for
VUF2274, probably via an ion-pair interaction.
VUF2274 Inhibits US28-mediated Signaling in HCMV-in-
fected Fibroblasts—Recently, some of us have reported that
infection of human foreskin fibroblasts with HCMV (strain
AD169) induces a consistent increase in PLC activity.2 To
investigate the role of HCMV-encoded GPCR US28 in this
process, a deletion mutant virus (referred to as HCMV-US28),
in which the open reading frame encoding US28 has been
disrupted, was generated.2 Fig. 5 shows the InsP turnover in
mock-, WT- (strain AD169), or HCMV-US28-infected HFFs.
Indeed, US28 expression is mainly responsible for constitutive
activation of PLC, because in HFFs infected with HCMV-
US28 inositol phosphate levels are dramatically reduced
(10.6  1.5% of WT-HCMV-induced InsP). The CX3C-chemo-
kine fractalkine partially inhibits (28  4%) the InsP produc-
tion in CMV-infected cells (Fig. 5), whereas it does not affect
the InsP signaling in HCMV-US28- or mock infected HFFs.
As observed with COS-7 cells, VUF2274 dose dependently in-
hibits US28-mediated signaling (inset, Fig. 5) in AD169-in-
fected HFFs with an IC50 of 776 nM (pIC50  6.11  0.04),
whereas the ligand does not affect InsP levels in mock or
HCMV-US28-infected cells (data not shown). As previously
reported (26), US28 expressed in AD169-infected HFFs binds
125I-RANTES with high affinity. In competition binding studies
VUF2274 completely displaces 125I-RANTES with an IC50 of
708 nM (pIC50  6.15  0.1; inset, Fig. 5).
VUF2274 Inhibits US28-mediated HIV-1 Entry—US28 has
been shown to be a broadly permissive co-receptor for HIV-1
when expressed in the presence of CD4 (10). To test the ability of
VUF2274 to block viral entry via US28, we used a reporter gene
assay. In this assay, HEK-293T cells expressing US28 and CD4
are infected by a luciferase-containing HIV-1 reporter virus. Con-
sequently, the level of cellular luciferase activity is proportional
to HIV-1 entry. Results obtained with this assay confirm that
FIG. 3. Role of the N terminus of US28 for the action of inverse
agonists. A, COS-7 cells expressing either WT- or (2–22)-US28 were
assayed for InsP accumulation in the presence of fractalkine (100 nM,
open bars), VUF2274 (10 M, gray bars), or medium alone (black bars).
Data are presented as percentage of the WT-US28-mediated response.
The average of three experiments, with each data point performed in
triplicate, is shown. B, COS-7 cells expressing either WT- (open circles)
or (2–22)-US28 (filled circles) were assayed for InsP accumulation in
the presence of different concentrations of VUF2274. Data are pre-
sented as percentage of the mediated response of the receptor. The
average of three experiments, with each data point performed in trip-
licate, is shown.
FIG. 4. Binding properties of 125I-RANTES and VUF2274 at
mutant and WT-US28 receptors. A, saturation binding with 125I-
RANTES was performed on COS-7 cells expressing (2–22)- (open
squares), E277A- (open circles), E277Q- (filled squares), or WT-US28
(filled circles). Data are presented as specific binding (cpm). A repre-
sentative experiment of three experiments, each performed in triplicate
is shown. B, COS-7 cells expressing E277A- (open circles), E277Q-
(filled squares), or WT-US28 (closed circles) were incubated with 0.3 nM
125I-RANTES in the presence of various concentrations of VUF2274.
Data are presented as percentage of the specific binding of the receptor.
The average of three experiments, with each data point performed in
triplicate, is shown.
FIG. 5. US28 mediates PLC activation in HCMV-infected fibro-
blasts. HFFs were mock, WT-HCMV- (strain AD169), or 28-HCMV-
infected and after 48 h were assayed for InsP accumulation in the
presence (open bars) or absence (filled bars) of fractalkine (100 nM). The
average of two experiments, with each data point performed in tripli-
cate, is shown. Inset, HCMV-infected HFFs were assayed for InsP
accumulation (filled circles) or 125I-RANTES binding (open circles) in
the presence of different concentrations of VUF2274. Data are pre-
sented as percentage of the HCMV-mediated response, defined as ab-
solute increase of InsP accumulation or 125I-RANTES binding above
mock infected cells. The average of three experiments, with each data
point performed in triplicate, is shown.
Nonpeptidergic Inverse Agonists for the HCMV-encoded US28 5175
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
US28 shows HIV-1 co-receptor properties. Luciferase activity is
increased20-fold in the presence of US28 when compared with
cells expressing CD4 alone (fig. 6A). VUF2274 was tested at
several concentrations and it showed a dose-dependent inhibi-
tory effect of US28-mediated viral entry (Fig. 6B). At 106 M,
VUF2274 reduces HIV-1 entry to 41  8% of control cells.
As a control, VUF2274 was tested on 293-T cells expressing
CD4 and CCR5. No inhibition of viral entry was observed (data
not shown), confirming the specificity of action of VUF2274.
DISCUSSION
Using the US28-mediated constitutive activation of PLC as a
screening approach, we have identified the small nonpeptider-
gic molecule VUF2274 as a full inverse agonist at the HCMV-
encoded chemokine receptor US28. Possible interferences of
VUF2274 with G proteins or other downstream components in
the InsP signaling cascade were ruled out using different
GPCRs as controls. Several analogues of VUF2274 were sub-
sequently tested. Several emerging points are noteworthy: the
piperidine ring as well as the hydroxyl group and the chloro-
substituent at the phenyl ring represent important moieties for
the activity of VUF2274. On the other hand, a higher degree of
freedom is tolerated at the benzhydryl moiety, where an in-
crease in the lyphophilicity or the removal of the cyano group is
well accepted. We are currently synthesizing other analogues
to develop more refined structure-activity relationships and
obtain molecules with an increased affinity for the receptor.
VUF2274 dose-dependently displaces 125I-RANTES binding
to US28, apparently with a noncompetitive behavior, as shown
by the marked decrease of the Bmax value of
125I-RANTES in
the presence of VUF2274. Chemokines are relatively large
peptides that interact mainly with the extracellular part of the
receptor, such as the N terminus and extracellular loops (21–
23). On the other hand, small nonpeptidergic compounds typi-
cally have interaction points located in the TM domains of
GPCRs. In fact, different studies have shown that nonpeptide
antagonists for peptide receptors, such as the glucagon receptor
(27) and the chemokine receptor CCR3 (28), often act as allos-
teric antagonists and show a noncompetitive behavior. Simi-
larly, mutational analysis performed on US28 suggests that
chemokines and VUF2274 bind to different epitopes of the
receptor. In fact, the N terminus deletion mutant (2–22)-
US28 does not bind any of the tested chemokines, whereas its
constitutive signaling is still inhibited by VUF2274 with a
similar potency as observed for WT-US28. Taken together,
these data prove that the N terminus of US28 is a determinant
for chemokine binding but not for the small compound
VUF2274. These results, together with the noncompetitive be-
havior shown in saturation binding assays, suggest that dis-
placement of the CC-chemokine RANTES is the result of a
change in the conformation of the receptor allosterically in-
duced by VUF2274, and not because of competition for the
same binding site. This is further corroborated by the fact that
RANTES cannot reverse the inverse agonistic effect of
VUF2274 in the InsP assay.
In line with these findings is our observation that mutation
of the glutamic acid residue Glu277 in TM 7 of US28 is not
important for RANTES binding, whereas it is a crucial inter-
action partner for VUF2274, possibly through an ion-pair in-
teraction with the basic nitrogen of the piperidine moiety. A
glutamic acid residue is highly conserved in this position
within the seventh transmembrane domain of chemokine re-
ceptors (29), whereas acidic residues are rare in this position in
other GPCRs. A previous study (29) has indeed identified this
conserved glutamic acid as a critical residue for high affinity
binding to CCR2 of a class of small antagonists that share some
common features with VUF2274, such as a piperidine moiety
and bulky aromatic groups. Docking of VUF2274 in the US28
in silico model (Fig. 7) suggests various aromatic residues as
potential interaction partners, such as Tyr40 in TM-1, Phe111
and Tyr112 in TM-3, Tyr244 in TM-6, and Phe281 in TM-7.
Further mutagenesis of US28 needs to be performed to confirm
these hypotheses and will help in refining our ideas on recep-
tor-ligand interactions.
To study the action of VUF2274 on viral activity, we inves-
tigated the effect of VUF2274 in HCMV-infected fibroblasts.
HCMV infection is accompanied by activation of several signal-
ing pathways in infected cells (30, 31), among which is a sus-
tained increase in the intracellular levels of inositol phos-
phates.2 Indeed, US28 expression appears to be mostly
responsible for activation of PLC, but is not the only player,
because cells infected with the deletion mutant virus US28
still have inositol phosphate levels higher than mock infected
cells (Fig. 5). We hypothesize that this residual activation could
be mediated by one of the other GPCRs encoded by HCMV
(namely US27, UL33, and UL78). At present there is increas-
ing evidence that also UL33 displays constitutive activity in
the InsP assay when transiently transfected in COS-7 cells
(17)4 and is not affected by VUF2274. We are currently gener-
4 P. Casarosa and Y. Gruijthuijsen, manuscript in preparation.
FIG. 6. Inhibition of US28-mediated HIV-1 entry by VUF2274.
A, HEK293-T cells were cotransfected with CD4 and US28 or CD4 alone
and infected with the luciferase-containing HIV-1 reporter virus. Data
are presented as relative light units (RLU). The average of three ex-
periments, with each data point performed in triplicate, is shown. B,
HEK293-T cells co-transfected with CD4 and US28 were incubated
with different concentrations of VUF2274 or Me2SO (negative control)
and infected with the luciferase-containing HIV-1 reporter virus. Data
are presented as percentage of US28 co-receptor activity, defined as
absolute increase of US28-mediated viral entry above values obtained
for cells transfected with CD4 alone. The average of two experiments,
with each data point performed in triplicate, is shown.
FIG. 7. Model of VUF2274 bound to US28. VUF2274 is accommo-
dated within US28 TM helices (in blue). The residue Glu277 (in yellow)
is shown interacting with the nitrogen in the piperidine moiety of
VUF2274, additional potential interaction partners are shown in purple
and described in the text.
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ating other deletion mutant viruses, such as 33 (lacking
UL33), which will help to better understand the physiological
relevance of these observations.
Infection of fibroblasts with HCMV offers a relevant model
for the pharmacological study of US28, because it closely re-
sembles the pathophysiological situation. In this condition,
US28 expression is regulated by the virus and its constitutive
signaling is not a potential artifact because of overexpression. In
line with data obtained in COS-7 cells, VUF2274 dose depend-
ently inhibited US28-mediated signaling in HCMV-infected
fibroblasts. These results confirm the action of VUF2274 as an
inverse agonist at US28 in a physiologically relevant model sys-
tem. It is, however, noteworthy that maximal inhibition produced
by VUF2274 on virus-infected cells is less pronounced (maximal
inhibition is 70% of HCMV-induced InsP accumulation) than
observed in COS-7 cells transfected with US28 receptor cDNA.
This discrepancy might be because of differences in US28 expres-
sion in the two systems, or possibly because of different US28
coupling to accessory proteins in the different cell lines. More-
over, it is possible that HCMV encodes some additional signaling
partner for US28 that could alter US28 behavior and that would
not be present in the transfected system.
US28 is an early gene, being transcribed as early as 2 h after
HCMV infection of permissive cells, such as fibroblasts (32).
Consequently, cells permissive to HCMV infection express a
receptor that functions in the absence of any ligand and may
influence the cellular machinery early after infection. Notably,
US28 constitutively activates pathways such as PLC and NF-
B, which are important for viral replication (33–35). US28 is
transcribed not only in cells permissive to CMV infection, but
also in latently infected cells, such as monocytes (36), suggest-
ing that US28 may affect a wide range of cell types. In mono-
cytes, the transcription factor NF-B promotes expression of
over 100 target genes, mostly involved in the regulation of the
immune response (37). It is suggestive to propose that US28,
through activation of PLC and NF-B pathways, might alter
expression of such proteins, resulting in alteration of the im-
mune response in favor of viral survival and spreading.
At present, the biological role of US28 in viral pathogenesis
is still unclear. US28 has been suggested to act as a chemokine
scavenger (38). Moreover, US28 can induce smooth muscle cell
migration (11). Finally, the possible implications of the high
constitutive activity of US28 in the pathogenesis of CMV infec-
tion have not been established yet. Studies conducted with a
US28 deletion mutant virus have shown that US28 is not
required for viral growth in culture (26), suggesting that its
role is important for viral pathogenesis in vivo.
The lack of in vivo systems because of the high species
specificity of HCMV makes the direct analysis of the function of
US28 difficult. Generation of US28 knock-in mice might repre-
sent a good system for the analysis of this receptor. This ap-
proach has been very successful for ORF74 (39). Moreover, the
recent discovery that chimpanzee CMV also encodes a US28
gene (NCBI accession number NP-612800) might offer an ad-
ditional animal model. The small inverse agonist VUF2274
provides a tool to investigate a potential role of US28 and its
constitutive activity in activating a cell to allow or enhance
viral replication in vivo.
Finally, different clinical studies (40, 41) have suggested that
HCMV infection is a co-factor in HIV disease progression. In for
example, HIV-positive infants CMV infection increases the
chances of progression to AIDS, impaired brain growth, and
motor deficits (41). Cellular entry of HIV-1 is mediated via
interaction of the viral glycoprotein 120 with CD4 and a co-
receptor, which belongs to the chemokine receptor family. The
best characterized co-receptors are CCR5, which mediates en-
try of monotropic (R5) HIV strains, and CXCR4, which medi-
ates entry of lymphotropic (X4) HIV strains. The HCMV-en-
coded US28 can also enhance viral entry for both R5- and
X4-tropic HIV strains in vitro (10), giving a molecular basis to
the epidemiological link between HCMV and HIV-1 infection.
Our results with 293T cells confirm US28 as a potential co-
receptor for CCR5-tropic HIV strains. The inverse agonist
VUF2274 at a concentration of 1 M inhibits viral entry by 60%,
suggesting that small ligands acting at US28 might have anti-
HIV properties. Further studies must be undertaken to de-
termine in detail how VUF2274 blocks HIV-1 entry.
VUF2274 might inhibit glycoprotein 120 binding at US28, or
inhibit a receptor conformational change necessary for viral
fusion, or alternatively induce US28 internalization. The var-
ious mechanisms have been previously suggested for differ-
ent inhibitors of HIV entry that target human chemokine
(co)receptors (25, 42).
Similarly, the physiological relevance of US28 as co-receptor
for HIV-1 still remains to be determined. There is evidence that
cellular co-infection with HIV and CMV can occur in vivo, in e.g.
the brain, retina, and lungs (43, 44). CCR5 expression in the
brain is very low (45), giving rise to the possibility that different
co-receptors, among which US28, might serve for HIV entry and
are related to the HIV-related progression of dementia.
In conclusion, we show that the small nonpeptidergic molecule
VUF2274 is a full inverse agonist at the HCMV-encoded chemo-
kine receptor US28. Moreover, VUF2274 inhibits US28-medi-
ated HIV-1 infection. To our knowledge, this is the first example
of a small inverse agonist targeted against a viral encoded GPCR.
We suggest that binding of VUF2274 locks the receptor US28 in
an inactive conformation and allosterically modulates chemokine
binding at US28. The identification of an inverse agonist pro-
vides a tool for further dissecting the role of US28 and its consti-
tutive activity in HCMV infection. In addition, it might serve as
a potential lead for innovative antiviral drug design.
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